Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Cardiovasc Res ; 78(1): 167-74, 2008 Apr 01.
Article in English | MEDLINE | ID: mdl-18192239

ABSTRACT

AIMS: CD1d-restricted natural killer T (NKT) cells function by regulating numerous immune responses during innate and adaptive immunity. Depletion of all populations of CD1d-dependent NKT cells has been shown by several groups to reduce atherosclerosis in two different mouse models of the disease. In this study, we determined if removal of a single (V alpha 14) NKT cell population protects mice from the disease. METHODS AND RESULTS: Targeted deletion of the J alpha 18 gene results in selective depletion of CD1d-dependent V alpha 14 NKT cells in C57BL/6 mice without affecting the population of other NKT, NK, and conventional T cells. Therefore, to study the effect of V alpha 14 NKT cell depletion on the progression of atherosclerosis, we examined the extent of lesion formation using paired littermate LDL receptor null mice that were either +/+ or -/- for the J alpha 18 gene following the feeding of these mice a cholesterol- and fat-enriched diet for 8 weeks. At the end of the study, we found no difference in either serum total- or lipoprotein-cholesterol distributions between groups. However, quantification of atherosclerosis revealed that V alpha 14 NKT cell deficiency significantly decreased lesion size in the aortic root (20-28%) and arch (28-38%) in both genders of mice. By coupling the techniques of laser capture microdissection with quantitative real-time RT-PCR, we found that expression of the proatherogenic cytokine interferon (IFN)-gamma was significantly reduced in lesions from J alpha 18-/- mice. CONCLUSION: This study is the first to identify a specific subpopulation of NKT cells that promotes atherosclerosis via a mechanism appearing to involve IFN-gamma expression.


Subject(s)
Antigens, CD1/metabolism , Atherosclerosis/prevention & control , Killer Cells, Natural/immunology , Receptors, Antigen, T-Cell, alpha-beta/metabolism , Receptors, LDL/metabolism , T-Lymphocytes/immunology , Animals , Antigens, CD1d , Atherosclerosis/immunology , Atherosclerosis/metabolism , Atherosclerosis/pathology , CD3 Complex/metabolism , Cholesterol/blood , Disease Models, Animal , Down-Regulation , Female , Histocompatibility Antigens Class II/metabolism , Interferon-gamma/genetics , Interferon-gamma/metabolism , Interleukin-10/genetics , Interleukin-10/metabolism , Interleukin-4/genetics , Interleukin-4/metabolism , Male , Mice , Mice, Knockout , Microdissection/methods , Polymerase Chain Reaction , RNA, Messenger/metabolism , Receptors, Antigen, T-Cell, alpha-beta/deficiency , Receptors, Antigen, T-Cell, alpha-beta/genetics , Receptors, LDL/deficiency , Receptors, LDL/genetics
2.
Can J Physiol Pharmacol ; 84(1): 67-75, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16845892

ABSTRACT

Atherosclerosis is a multifactor, highly complex disease with numerous aetiologies that work synergistically to promote lesion development. One of the emerging components that drive the development of both early- and late-stage atherosclerotic lesions is the participation of both the innate and acquired immune systems. In both humans and animal models of atherosclerosis, the most prominent cells that infiltrate evolving lesions are macrophages and T lymphocytes. The functional loss of either of these cell types reduces the extent of atherosclerosis in mice that were rendered susceptible to the disease by deficiency of either apolipoprotein E or the LDL (low density lipoprotein) receptor. In addition to these major immune cell participants, a number of less prominent leukocyte populations that can modulate the atherogenic process are also involved. This review will focus on the participatory role of two "less prominent" immune components, namely natural killer (NK) cells and natural killer T (NKT) cells. Although this review will highlight the fact that both NK and NKT cells are not sufficient for causing the disease, the roles played by both these cells types are becoming increasingly important in understanding the complexity of this disease process.


Subject(s)
Atherosclerosis/immunology , Killer Cells, Natural/immunology , T-Lymphocyte Subsets/immunology , Animals , Antibody-Dependent Cell Cytotoxicity , Atherosclerosis/pathology , Humans , Immunity, Cellular , Immunity, Innate , Mice , Models, Animal
3.
J Lipid Res ; 45(5): 849-58, 2004 May.
Article in English | MEDLINE | ID: mdl-14967812

ABSTRACT

The effect of apolipoprotein A-II (apoA-II) on the structure and stability of HDL has been investigated in reconstituted HDL particles. Purified human apoA-II was incorporated into sonicated, spherical LpA-I particles containing apoA-I, phospholipids, and various amounts of triacylglycerol (TG), diacylglycerol (DG), and/or free cholesterol. Although the addition of PC to apoA-I reduces the thermodynamic stability (free energy of denaturation) of its alpha-helices, PC has the opposite effect on apoA-II and significantly increases its helical stability. Similarly, substitution of apoA-I with various amounts of apoA-II significantly increases the thermodynamic stability of the particle alpha-helical structure. ApoA-II also increases the size and net negative charge of the lipoprotein particles. ApoA-II directly affects apoA-I conformation and increases the immunoreactivity of epitopes in the N and C termini of apoA-I but decreases the exposure of central domains in the molecule (residues 98-186). ApoA-II appears to increase HL association with HDL and inhibits lipid hydrolysis. ApoA-II mildly inhibits PC hydrolysis in TG-enriched particles but significantly inhibits DG hydrolysis in DG-rich LpA-I. In addition, apoA-II enhances the ability of reconstituted LpA-I particles to inhibit VLDL-TG hydrolysis by HL. Therefore, apoA-II affects both the structure and the dynamic behavior of HDL particles and selectively modifies lipid metabolism.


Subject(s)
Apolipoprotein A-II/metabolism , Lipase/metabolism , Lipoproteins, HDL/metabolism , Liver/enzymology , Electrophoresis, Agar Gel , Esterification , Humans , Molecular Conformation , Particle Size , Phosphatidylcholine-Sterol O-Acyltransferase/isolation & purification , Phosphatidylcholine-Sterol O-Acyltransferase/metabolism , Static Electricity
4.
J Lipid Res ; 44(7): 1306-14, 2003 Jul.
Article in English | MEDLINE | ID: mdl-12700335

ABSTRACT

Human hepatic lipase (hHL) mainly exists cell surface bound, whereas mouse HL (mHL) circulates in the blood stream. Studies have suggested that the carboxyl terminus of HL mediates cell surface binding. We prepared recombinant hHL, mHL, and chimeric proteins (hHLmt and mHLht) in which the carboxyl terminal 70 amino acids of hHL were exchanged with the corresponding sequence from mHL. The hHL, mHL, and hHLmt proteins were catalytically active using triolein and tributyrin as substrates. In transfected cells, the majority of hHLs bound to the cell surface, with only 4% of total extracellular hHL released into heparin-free media, whereas under the same conditions, 61% of total extracellular mHLs were released. Like mHL, hHLmt showed decreased cell surface binding, with 68% of total extracellular hHLmt released. To determine the precise amino acid residues involved in cell surface binding, we prepared a truncated hHL mutant (hHL471) by deleting the carboxyl terminal five residues (KRKIR). The hHL471 also retained hydrolytic activity with triolein and tributyrin, and showed decreased cell surface binding, with 40% of total extracellular protein released into the heparin-free media. These data suggest that the determinants of cell surface binding exist within the carboxyl terminal 70 amino acids of hHL, of which the last five residues play an important role.


Subject(s)
Cell Membrane/metabolism , Lipase/biosynthesis , Lipase/chemistry , Liver/enzymology , Amino Acid Sequence , Animals , CHO Cells , Catalysis , Chromatography , Cricetinae , DNA, Complementary/metabolism , Dose-Response Relationship, Drug , Heparin/pharmacology , Humans , Kinetics , Mice , Molecular Sequence Data , Plasmids/metabolism , Protein Binding , Protein Structure, Tertiary , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , Sepharose/pharmacology , Time Factors , Transfection , Triglycerides/chemistry , Triolein/chemistry
5.
J Lipid Res ; 44(4): 733-41, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12562872

ABSTRACT

We have previously shown that hepatic lipase (HL) is inactive when bound to purified heparan sulfate proteoglycans and can be liberated by HDL and apolipoprotein A-I (apoA-I), but not by LDL or VLDL. In this study, we show that HDL is also able to displace HL directly from the surface of the hepatoma cell line, HepG2, and Chinese hamster ovary cells stably overexpressing human HL. ApoA-I is more efficient at displacing cell surface HL than is HDL, and different HDL classes vary in their ability to displace HL from the cell surface. HDL2s have a greater capacity to remove HL from the cell surface and intracellular compartments, as compared with the smaller HDL particles. The different HDL subclasses also uniquely affect the activity of the enzyme. HDL2 stimulates HL-mediated hydrolysis of VLDL-triacylglycerol, while HDL3 is inhibitory. Inhibition of VLDL hydrolysis appears to result from a decreased interlipoprotein shuttling of HL between VLDL and the smaller, more dense HDL particles. This study suggests that high HDL2 levels are positively related to efficient triacylglycerol hydrolysis by their ability to enhance the liberation of HL into the plasma compartment and by a direct stimulation of VLDL-triacylglycerol hydrolysis.


Subject(s)
Lipase/metabolism , Lipoproteins, HDL/physiology , Lipoproteins, VLDL/metabolism , Liver/enzymology , Membrane Glycoproteins , Triglycerides/metabolism , Apolipoprotein A-I/isolation & purification , Apolipoprotein A-I/metabolism , Apolipoprotein A-I/physiology , Cell Line, Tumor , Humans , Hydrolysis , Lipase/isolation & purification , Lipoproteins, HDL/isolation & purification , Lipoproteins, HDL/metabolism , Lipoproteins, HDL2
SELECTION OF CITATIONS
SEARCH DETAIL
...